Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly
poor prognosis. For decades, the best available systemic therapy was platinum plus …

Small cell lung cancer (SCLC) is an aggressive tumor characterized by rapid doubling time
and high propensity for early development of disseminated disease. Although most patients …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor of the lung with a
tendency to metastasize widely early in the course of the disease. The VA staging system …

Background Accounting for 14% of lung cancer, small cell lung cancer (SCLC) is a highly
aggressive neuroendocrine malignancy with rapid proliferation, early spread, and poor …

Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients
are diagnosed at limited stage. The median survival remains to be around 15–20 months …

Background Few options exist for treatment of patients with small-cell lung cancer (SCLC)
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic …

Highlights•ICIs have shifted the treatment paradigm to improve overall survival in advanced
SCLC.•The magnitude of immune-chemotherapy strategy is still modest. The …

Small‐cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases;
however, it is characterized by easy relapse and low survival rate, leading to one of the most …